00:43 , Jun 29, 2018 |  BC Innovations  |  Product R&D

Highly personal

Pact Pharma Inc. has raised $120 million in venture financing to tackle one of the most complex forms of personalized medicine proposed to date: neoantigen-targeted T cells. Backed by Alphabet Inc.’s GV, the company is...
21:47 , Mar 19, 2018 |  BC Extra  |  Company News

Management tracks: J&J, Alder, CVS

Johnson & Johnson (NYSE:JNJ) said EVP and CFO Dominic Caruso will retire in September. He is succeeded by VP of investor relations Joseph Wolk. Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) said President and CEO Randall Schatzman will...
18:03 , Sep 1, 2017 |  BC Week In Review  |  Company News

CSL Behring acquires Calimmune

The CSL Behring subsidiary of CSL Ltd. (ASX:CSL) said it will acquire gene therapy company Calimmune Inc. (Tucson, Ariz.), gaining two ex vivo autologous gene therapy candidates and two stem cell therapy technologies. Calimmune will...
20:33 , Aug 28, 2017 |  BC Extra  |  Company News

CSL Behring acquires Calimmune

The CSL Behring subsidiary of CSL Ltd. (ASX:CSL) said it will acquire gene therapy company Calimmune Inc. (Tucson, Ariz.), gaining two ex vivo autologous gene therapy candidates and two stem cell therapy technologies. Calimmune will...
20:26 , Dec 9, 2016 |  BC Week In Review  |  Company News

Cincinnati Children's Hospital, Calimmune deal

Calimmune gained rights to develop and commercialize ex vivo autologous gene therapies using the hospital's lentiviral hemoglobin subunit gamma (HBG) globin gene construct to treat sickle cell disease and beta thalassemia. Calimmune will combine the...
07:00 , Jul 18, 2016 |  BC Extra  |  Company News

Management tracks

Cancer and neurology company e-Therapeutics plc (LSE:ETX) said Malcolm Young resigned as CEO and a director. The company is searching for a replacement. Gene therapy company Calimmune Inc. (Tucson, Ariz.) promoted Jeffrey Bartlett to CSO...
07:00 , Mar 31, 2016 |  BC Innovations  |  Tools & Techniques

Postmodern ART

The next frontier in HIV therapy is moving patients beyond antiretroviral therapy (ART), which involves daily cocktails of compounds that block replication and spread of the virus, taken either as separate or combined formulations. Because...
00:58 , Mar 24, 2016 |  BC Extra  |  Company News

Management tracks

Huya Bioscience International LLC (San Diego, Calif.), which is developing oncology and cardiovascular candidates sourced in China, named John Ratliff president and CEO. He replaces founder and CEO Mireille Gillings, who will continue as executive...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Company News

Asklepios, Calimmune deal

Asklepios granted Calimmune rights to Asklepios’ adeno-associated virus (AAV) gene therapy technologies, which Calimmune plans to use in a Phase I/II trial of a gene therapy to treat osteoarthritis. Asklepios will receive an upfront payment...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Company News

St. Jude Children’s Research Hospital, Calimmune deal

St. Jude granted Calimmune exclusive, worldwide rights to develop and commercialize products using a stable packaging cell line that produces lentiviral vectors. Calimmune will use the technology for its lentiviral vector bioproduction process, which the...